China Biologic Products Holdings, Inc. (CBPO) Company Bio
China Biologic Products engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in China. The company is based in Beijing, the China.
CBPO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for China Biologic Products Holdings Inc. To summarize, we found that China Biologic Products Holdings Inc ranked in the 51th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of China Biologic Products Holdings Inc, consider:
The company's debt burden, as measured by earnings divided by interest payments, is 300.33 -- which is good for besting 97.07% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 0% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
CBPO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 68.34% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CBPO, try LH, UHS, HCSG, NVST, and DGX.